Health & Safety Industry Today

MRSA Drugs Market Growing Demand and Top Key Player Analysis 2023; By Drug Class, MRSA Type and Disease Indications

MRSA Drugs Market Provide Country Level Analysis of the Market with Respect to the Current Market Size and Future Prospective.
Published 08 March 2018

MRSA drugs are used to combat Methicillin-resistant Staphylococcus aureus (MRSA) strains of bacteria. MRSA infections are resistant to many antibiotics and are classified as community-acquired (CA-MRSA) and hospital-acquired (HA-MRSA). Common infections caused by MRSA are bone and joint infections, skin infections, bacteremia and others.

The Global MRSA Drugs Market is expected to reach USD 4,312.2 million by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.

According to bulletin of the atomic scientists, about 10 million people in the US (3.6 percent of the population) are immune-compromised. The World Health Organization estimated that about 36.7 million people had HIV/AIDS worldwide in 2016. Thus, the rising immune-compromised population is expected to propel the market growth over the review period. Additionally, growing geriatric population projected to support the growth of the market since older people are more susceptible to MRSA infections. World Health Organization estimated that during 2015-2050, the proportion of the world's population will be nearly double from 12% to 22% and by 2020, the number of people aged over 60 years likely to outnumber children younger than 5 years.

Market Dynamics of Global MRSA drugs Market:


The market drivers of global MRSA drugs market are growing number of hospitals and volume of treatment, growing population of elderly and immune compromised patients, growing awareness, government initiatives and programs to control MRSA, and growing prevalence rate of MRSA. Growing bacterial resistance


The market is restrained by factors such as menace of spurious and counterfeited drugs, low healthcare expenditure in the underdeveloped regions and others.

The prohibitive cost of novel and patented MRSA drugs is the critical restraint of the MRSA drugs market. For example, Tigecycline 50 mg dose in India costs Rs. 2,990 approximately, which is prohibitive for most of the population.

Get a Brochure of This Report @ .

Key Players in the Global MRSA Drugs Market

Some of the key players profiled in the report are

  • Merck KGaA,
  • Olon,
  • Allergan,
  • Baxter,
  • Theravance Biopharma,
  • Pfizer,
  • Mylan N.V
  • Novartis

Regional Analysis:

The global MRSA drugs market is segmented into regions such as North America, Europe, Asia pacific and others so as to have a clear view of the differential market potential and future market equity.

North America commanded the lion’s share of the market in 2016, which is expected to generate USD 1,602.5 million by 2023, growing at a CAGR of 4.6 %. Hospital Readmissions Reduction Program established under Affordable Care Act (ACA) financially penalizes hospitals for higher than expected 30-day readmission rates for diseases such as pneumonia. The financial incentive for reducing readmissions and the rising cost of non-compliance is expected to benefit the MRSA drugs market in the U.S. The excellent reimbursement scenario in the U.S. coupled with the high public expenditure on healthcare accounting for 16% of total GDP is a huge boost to the market.

Europe is the second largest market led by Germany and France due to their large economies. However south European nations such as Italy, Portugal, and Spain have higher prevalence of MRSA and are expected to be the fastest growing market. Scandinavian region countries such as Iceland, Norway, and Finland have very poor rates of MRSA infections which drive down their markets.

Grab Attractive Discount on This Report @ .

Asia Pacific region is expected to be led by China and India due to the fast growing healthcare sector and large unmet needs. However, countries such as Japan, Vietnam, Indonesia, South Korea, Philippines, Sri Lanka, etc. have higher prevalence and are expected to generate faster growth.

Gulf nations such as Saudi Arabia, Kuwait, Jordan, and the UAE are expected to dominate the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.


About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.


Market Research Future

+1 646 845 9312


Other Industry News

Ready to start publishing

Sign Up today!